Emerging Companies
The BIO Emerging Companies Section (ECS) works to help provide a favorable business environment for small biotech companies. Ninety percent of BIO research and development members are small companies, operating on a modest budget. ECS is dedicated to helping the next generation of biotech pioneers flourish.
Cures Acceleration Network: Legislative Text
The Cures Acceleration Network, passed in the recently enacted healthcare reform bill, will provide funding to public and private entities to bridge the gap between basic research and cures for patients.
Read the legislative text
Therapeutic Discovery Project Credit statute: Legislative text included as part of H.R. 3590, the Patient Protection and Affordable Care Act
BIO advocated for the recently enacted new Therapeutic Discovery Project Credit program, which was created as a unique opportunity for companies in a loss position to earn tax credits for up to 50 percent of many of their R&D activities, and at their option, exchange these credits for a grant, on 1:1 basis.
Read about the program
SBIR Backgrounder: Strengthen the SBIR Program
This backgrounder emphasizes the importance of strengthening the SBIR program to support bringing scientific innovation to the public.
Read the backgrounder
Small Business Early Stage Investment Program: Legislative Text
The Small Business Early Stage Investment Program would provide matching funds for investment companies who invest in small, high tech companies, including biotech firms.
Read the legislative text
Read BIO’s press release
| 
